Key result
Low-dose intravenous thrombolytic therapy with alteplase successfully treated mechanical aortic valve thrombosis in a 42-year-old female, improving valve movement and reducing transvalvular gradients.
Why the study?
Mechanical prosthetic valves are thrombogenic and require anticoagulation to prevent thrombosis and reduce catastrophic stroke risk.
Does low-dose, slow-infusion alteplase improve valve hemodynamics and symptoms in a patient with mechanical aortic valve thrombosis?
Case Report (n=1)
Does low-dose, slow-infusion alteplase improve valve hemodynamics and symptoms in a patient with mechanical aortic valve thrombosis?
Low-dose, slow-infusion alteplase successfully and safely treated mechanical aortic valve thrombosis, significantly improving valve hemodynamics and patient symptoms.
Supports low-dose tPA in select mechanical aortic valve thrombosis; hypothesis-generating and should not yet change practice.
Mechanical prosthetic valves, like all foreign bodies, are thrombogenic, requiring anticoagulation to avoid thrombosis and reduce the risk of catastrophic stroke. We reported a case of a 42-year-old female that developed mechanical valve thrombosis and was successfully treated with low infusion thrombolytic therapy using alteplase (tPA, tissue plasminogen activator).
No takes yet. Share an insight, caveat, or question.
Mandal et al. (2022) conducted a case report in Mechanical Aortic Valve Thrombosis (n=1). Alteplase (tPA) was evaluated on Improvement in valve movement and transvalvular gradient. Low-dose intravenous thrombolytic therapy with alteplase successfully treated mechanical aortic valve thrombosis in a 42-year-old female, improving valve movement and reducing transvalvular gradients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: